YIV-818

**YIV-818** is a first-in-class systems biology drug derived from optimized water extracts of **Rubia cordifolia**, developed by **Yiviva** primarily for hormone-driven cancers. Its key active compound, deoxybouvardin (RA-V), alongside RA-VII, downregulates androgen receptor (AR) and AR variants by inhibiting protein synthesis, inhibits glucocorticoid receptor (GR) activity, modulates epigenetic markers such as reducing Brd2/Brd4 and H3K27Ac levels, and impacts AR target gene expression. It demonstrates synergistic effects with AR inhibitors like apalutamide, darolutamide, and enzalutamide, suppressing tumor growth in castration-resistant prostate cancer (CRPC) models both in vitro and in vivo, with a established safety profile supporting its potential as a chemopreventive and anti-cancer agent.[1][2][7]

Other names

RA-V containing extract from Rubia cordifolia